Padma P. Tadi Uppala Discussed Research Analyzing Natural Therapies to Combat COVID-19

Video

A presentation from the AACR Virtual Meeting: COVID-19 and Cancer detailed a literature review of natural therapeutics and remedies to combat the SARS CoV-2 virus.

CancerNetwork® spoke with Padma P. Tadi Uppala, professor and director of the Public Health Program at Andrews University, regarding her research from the AACR Virtual Meeting: COVID-19 and Cancer.

Uppala, along with her research partners, performed an exploratory analysis about evidence-based natural therapies and foods that naturally enhance the immune system with the goal of combatting the SARS CoV-2 virus.

“It’s a systematic literature review of evidence-based natural therapies to prevent and treat COVID-19,” explained Uppala. “It’s based on the fact that SARS CoV-2 dysregulates the innate immune system, so I wanted to look at literature to find if natural therapies can strengthen the innate immune system.”

The results, which relied heavily on data about the 1918 Spanish Flu as well as existing literature, found that foods such as blueberries, garlic, and probiotics were shown to improve natural killer activity, while Vitamin C, Vitamin D, Zinc, and selenium were integral in immunity.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.